OPEN END-TURBO-OPTIONSSCHEIN - MORPHOSYS Share Price

Certificat

DE000HS4GY36

Real-time BOERSE MUENCHEN 11:32:04 21/05/2024 am IST
3.11 EUR 0.00% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - MORPHOSYS
Current month+7.99%
1 month+1.63%
Date Price Change
21/24/21 3.11 0.00%
20/24/20 3.11 -3.72%
17/24/17 3.23 -1.52%
16/24/16 3.28 +7.89%
15/24/15 3.04 -0.33%

Real-time BOERSE MUENCHEN

Last update May 21, 2024 at 11:32 am IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying MORPHOSYS AG
Issuer HSBC
WKN HS4GY3
ISINDE000HS4GY36
Date issued 29/01/2024
Strike 38.09
Maturity Unlimited
Parity 10 : 1
Emission price 0.25
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.28
Lowest since issue 0.26

Company Profile

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Sector
-
More about the company

Ratings for MorphoSys AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: MorphoSys AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.1 EUR
Average target price
58.71 EUR
Spread / Average Target
-13.78%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW